Cheung, Yee-Ming M. http://orcid.org/0000-0003-3875-5698
Cromwell, Grace E.
Tolaney, Sara M.
Min, Le
McDonnell, Marie E.
Article History
Received: 9 September 2021
Accepted: 2 December 2021
First Online: 9 January 2022
Declarations
:
: SMT receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, and Seattle Genetics; has served as an advisor/consultant to AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Celldex, Paxman, Puma, Silverback Therapeutics, G1 Therapeutics, Gilead, AbbVie, Athenex, OncoPep, Outcomes4Me, Kyowa Kirin Pharmaceuticals, Daiichi-Sankyo, and Samsung Bioepsis Inc. All other authors have no funding or conflicts of interest to disclose.
: This study has been approved by the MassGeneralBrigham Institutional Review Board (IRB).
: Given the retrospective and low risk nature of this study, formal participant consent and consent to publish was not required.